Multi-Center, Randomized, Double-Blind, Phase III Trial to Assess the Immunogenicity and Safety of Primary Vaccination With NBP606 in Healthy Infants
Phase of Trial: Phase III
Latest Information Update: 01 Feb 2019
Price : $35 *
At a glance
- Drugs NBP 606 (Primary) ; Pneumococcal vaccine
- Indications Pneumococcal infections
- Focus Registrational; Therapeutic Use
- Sponsors SK Chemicals
- 21 Jun 2016 Planned primary completion date changed from 1 Jul 2015 to 1 Jun 2016.
- 21 Jun 2016 Planned End Date changed from 1 Jul 2015 to 1 Dec 2016.
- 21 Jun 2016 Status changed from not yet recruiting to recruiting.